Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform

Biotechnology and Bioengineering(2022)10.1002/bit.28313Source: DataRank Database

αCT1 peptide sensitizes glioma cells to temozolomide in a glioblastoma organoid platform is a research paper published in Biotechnology and Bioengineering (2022). On theSindex it has a DataRank of 0. It has been cited 21 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access21 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 1.80)OA: hybridTopics (30)Linked Datasets (8)DataCite Reuse (8)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Thomas J. DePalma ORCID,Hemamylammal Sivakumar ORCID,Louisa Mezache,Miranda M. Tallman,Monica Venere ORCID

Live enrichment

PubMed:36544242 PMC:PMC12707316 OpenAlex:https://openalex.org/W4313453239

NCI NIH HHS

Grant: R21 CA229027

NHLBI NIH HHS

Grant: R01 HL148736

NHLBI NIH HHS

Grant: R01 HL165751

NCI NIH HHS

Grant: R21 CA250118

NCI NIH HHS

Grant: R21 CA263137

Pelotonia

Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

College of Engineering, Ohio State University

American Cancer Society

National Institutes of Health

FWCI

1.80

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1002/bit.28313

publisherhttps://doi.org/10.1002/bit.28313

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/bit.28313

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/bit.28313

publisherhttps://analyticalsciencejournals.onlinelibrary.wiley.com/doi/pdf/10.1002/bit.28313

Fields of Study

Connexins and lens biologyNanoplatforms for cancer theranosticsAdvanced Fluorescence Microscopy Techniques

MeSH Terms

TemozolomideGlioblastomaGliomaHumansPeptidesSignal TransductionConnexin 43Cell Line, Tumor

Keywords

TemozolomideGliomaCancer researchOrganoidBrain tumorGlioblastomaConnexinMedicineEffluxOncologyInternal medicineBiologyPathologyNeuroscienceCell biologyGap junctionIntracellularconnexin 43Organoids

Sustainable Development Goals

SDG 0: Good health and well-being

Additional file 3 of Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways

10.6084/m9.figshare.26750729.v1figshare

Additional file 3 of Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways

10.6084/m9.figshare.26750729figshare

Additional file 4 of Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways

10.6084/m9.figshare.26750732.v1figshare

Additional file 4 of Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways

10.6084/m9.figshare.26750732figshare

Additional file 1 of Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways

10.6084/m9.figshare.26750723.v1figshare